The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients
Open accessAbstract
Previous studies have investigated the potential atherogenicity and thrombogenicity of triglyceride-rich lipoprotein (TRL) remnants by isolating them from plasma within a remnant-like particle (RLP) fraction, using an immunoaffinity gel containing specific anti-apoB-100 and anti-apoA-I antibodies. In order to characterize lipoproteins in this RLP fraction and to determine to what extent their composition varies from one individual to another, we have used automated gel filtration chromatography to determine the size heterogeneity of RLP isolated from normolipidemic control subjects (n = 8), and from type III (n = 6) and type IV (n = 9) hyperlipoproteinemic patients, who by selection had similarly elevated levels of plasma triglyceride (406 +/- 43 and 397 +/- 35 mg/dl, respectively). Plasma RLP triglyceride, cholesterol, apoB, apoC-III, and apoE concentrations were elevated 2- to 6-fold (P < 0. 05) in hyperlipoproteinemic patients compared to controls. RLP fractions of type III patients were enriched in cholesterol and apoE compared to those of type IV patients, and RLP of type IV patients were enriched in triglyceride and apoC-III relative to those of normolipidemic subjects. In normolipidemic subjects, the majority of RLP had a size similar to LDL or HDL. The RLP of hyperlipoproteinemic patients were, however, larger and were similar in size to TRL, or were intermediate in size (i.e., ISL) between that of TRL and LDL. Compared to controls, ISL in the RLP fraction of type III patients were enriched in apoE relative to apoC-III, whereas in type IV patients they were enriched in apoC-III relative to apoE. These results demonstrate that: 1) RLP are heterogeneous in size and composition in both normolipidemic and hypertriglyceridemic subjects, and 2) the apoE and apoC-III composition of RLP is different in type III compared to type IV hyperlipoproteinemic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remnant lipoproteins are enriched in cholesterol (both free and esterified) and are depleted in apoC proteins and enriched in apoE (Figure 2).5–7”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several factors, including activating or inhibitory apolipoproteins (apoCII and apoCIII, respectively) on the TRL surface, and LpL availability, influence residence time in the circulation and the potential entry and retention of remnants within the arterial subendothelial space.5”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remnant particles may contain up to four-fold greater cholesterol content per particle than LDL.”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VLDL and remnants are also enriched in apoE and apoCIII, both implicated in binding and retention in the artery wall.5,71,125”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“The longer a remnant remains in the circulation, the more it becomes enriched with CE; the cholesterol content in these end-product remnants can exceed 7500 molecules per particle (vs. 2000–2700 in LDL).”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
The Metabolic Basis of Inherited Diseases
Winkelmann, R. K. (1972) · Archives of Dermatology · doi:10.1001/archderm.1972.01620110090032 · Cited by 1,769
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Havel, R. J., Kane, J. P., & Kashyap, M. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107171 · Cited by 528
The Familial Hyperlipoproteinemias
Marion, M. S. (1975) · Cited by 528
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Virgil Brown, W., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 491
Aalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450
Kowal, R. C., Herz, J., Weisgraber, K. H., Mahley, R. W., Brown, M. S., & Goldstein, J. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)87014-4 · Cited by 445
Nakajima, K., Saito, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 416
Self-citationModulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Handbook of Lipoprotein Testing
Rifai, N., Warnick, G. R., & Dominiczak, M. H. (2001) · Medical Entomology and Zoology · Cited by 384
Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat.
Shelburne, F., Hanks, J., Meyers, W., & Quarfordt, S. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109710 · Cited by 358
Mjos, O. D., Faergeman, O., Hamilton, R. L., & Havel, R. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108130 · Cited by 322
Windler, E., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314
Pagnan, A., Havel, R. J., Kane, J. P., & Kotite, L. (1977) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41603-7 · Cited by 236
de Silva, H. V., Lauer, S. J., Wang, J., Simonet, W. S., Weisgraber, K. H., Mahley, R. W., & Taylor, J. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42171-5 · Cited by 208
Kugiyama, K., Doi, H., Motoyama, T., Soejima, H., Misumi, K., Kawano, H., Nakagawa, O., Yoshimura, M., Ogawa, H., Matsumura, T., et al. (1998) · Circulation · doi:10.1161/01.cir.97.25.2519 · Cited by 187
Self-citationCampos, E., Nakajima, K., Tanaka, A., & Havel, R. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41527-5 · Cited by 182
Self-citationHuang, Y., von Eckardstein, A., Wu, S., Maeda, N., & Assmann, G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1834 · Cited by 181
Type III Hyperlipoproteinemia: Defective Metabolism of an Abnormal Apolipoprotein E
Gregg, R. E., Zech, L. A., Schaefer, E. J., & Brewer, H. B. (1981) · Science · doi:10.1126/science.7455696 · Cited by 180
Further Observations on the Activation and Inhibition of Lipoprotein Lipase by Apolipoproteins
KRAUSS, R. M., HERBERT, P. N., LEVY, R. I., & FREDRICKSON, D. S. (1973) · Circulation Research · doi:10.1161/01.res.33.4.403 · Cited by 174
Kinnunen, P. K. J., & Ehnholm, C. (1976) · FEBS Letters · doi:10.1016/0014-5793(76)80145-7 · Cited by 166
Ehnholm, C., Mahley, R. W., Chappell, D. A., Weisgraber, K. H., Ludwig, E. H., & Witztum, J. L. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.17.5566 · Cited by 157
Handbook of Lipoprotein Testing
SULLIVAN, D. R. (1998) · Pathology · doi:10.1016/s0031-3025(16)34905-4 · Cited by 132
Fredenrich, A., Giroux, L.-M., Tremblay, M., Krimbou, L., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37424-1 · Cited by 115
Self-citationAalto‐Setälä, K., Weinstock, P. H., Bisgaier, C. L., Wu, L., Smith, J. D., & Breslow, J. L. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39123-9 · Cited by 114
The hemostatic system and coronary heart disease
Hamsten, A. (1993) · Thrombosis Research · doi:10.1016/0049-3848(93)90221-9 · Cited by 109
Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study
McNamara, J. R., Shah, P. K., Nakajima, K., Cupples, L. A., Wilson, P. W. F., Ordovás, J. M., & Schaefer, E. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.6.1224 · Cited by 107
Self-citationDevaraj, S., Vega, G., Lange, R., Grundy, S. M., & Jialal, I. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00089-8 · Cited by 99
Cohn, J. S., Tremblay, M., Amiot, M., Bouthillier, D., Roy, M., Genest, J. J., & Davignon, J. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.1.149 · Cited by 96
Self-citationMcCollum Award Lecture, 1993: Triglyceride-rich lipoproteins and atherosclerosis—new perspectives
Havel, R. J. (1994) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/59.4.795 · Cited by 86
Uptake of Remnant Like Particles (RLP) in Diabetic Patients from Mouse Peritoneal Macrophages
Tomono, S., Kawazu, S., Kato, N., Ono, T., Ishii, C., Ito, Y., Shimizu, M., Shimoyama, M., Nakano, T., & Nakajima, K. (1994) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.1.98 · Cited by 76
Self-citationSchaefer, E. J., Wetzel, M. G., Bengtsson, G., Scow, R. O., Brewer, H. B., & Olivecrona, T. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38031-7 · Cited by 68
Krimbou, L., Tremblay, M., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37273-4 · Cited by 53
Self-citationA New Approach for the Detection of Type III Hyperlipoproteinemia by RLP-Cholesterol Assay
Nakajima, K., SAITO, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., & Murase, T. (1994) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.1.30 · Cited by 49
Self-citationImproved phenotyping of apolipoprotein E: application to population frequency distribution
Hill, J. S., & Pritchard, P. H. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.11.1871 · Cited by 48
Marcoux, C., Tremblay, M., Fredenrich, A., Jacques, H., Krimbou, L., Nakajima, K., Davignon, J., & Cohn, J. S. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00042-2 · Cited by 45
Self-citationRemnant-like lipoproteins stimulate whole blood platelet aggregation in vitro
Knöfler, R., Nakano, T., Nakajima, K., Takada, Y., & Takada, A. (1995) · Thrombosis Research · doi:10.1016/0049-3848(95)00044-5 · Cited by 41
Self-citationFielding, C. J., Frohlich, J., Moser, K. W., & Fielding, P. E. (1982) · Metabolism · doi:10.1016/0026-0495(82)90146-9 · Cited by 39
Quantification of human serum apolipoprotein AI by enzyme immunoassay.
Bury, J., & Rosseneu, M. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.2.247 · Cited by 37
Albers, J. J., Lodge, M. S., & Curtiss, L. K. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38265-1 · Cited by 33
Shimizu, H., Mori, M., & SAITO, T. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90033-z · Cited by 32
Fielding, C. J., Castro, G. R., Donner, C. C., Fielding, P. E., & Reaven, G. M. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38764-2 · Cited by 28
Remnant-Like Particle Cholesterol May Indicate Atherogenic Risk in Patients on Chronic Hemodialysis
Oda, H., Yorioka, N., Okushin, S., Nishida, Y., Kushihata, S., Ito, T., & Yamakido, M. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000190133 · Cited by 27
Triglyceride-rich lipoproteins and their role in atherogenesis
Gianturco, S. H., & Bradley, W. A. (1991) · Current Opinion in Lipidology · doi:10.1097/00041433-199110000-00009 · Cited by 27
Association of apolipoprotein E with α2-macroglobulin in human plasma
Krimbou, L., Tremblay, M., Davignon, J., & Cohn, J. S. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33316-2 · Cited by 26
Self-citationRemnant‐like Particles and Restenosis of Coronary Arteries after PTCA
Tanaka, A., Ejiri, N., Fujinuma, Y., Yui, K., Tamura, M., Nakajima, K., MOROHOSHI, M., Fujisawa, K., UCHIMURA, I., & Numano, F. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17369.x · Cited by 22
Self-citationMochizuki, M., Takada, Y., Urano, T., Nagai, N., Nakano, T., Nakajima, K., & Takada, A. (1996) · Thrombosis Research · doi:10.1016/0049-3848(96)00033-3 · Cited by 18
Self-citationSekihara, T., Nakano, T., & Nakajima, K. (1996) · PubMed · Cited by 16
Self-citationPostprandial Hyperlipemia and Coronary Artery Disease
Nakamura, H., Ikewaki, K., NISHIWAKI, M., & Shige, H. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17340.x · Cited by 15
Postprandial remnant-like particles and coronary artery disease
Ikewaki, K., Shige, H., Nakajima, K., & Nakamura, H. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)93348-0 · Cited by 9
Self-citationPostprandial Hyperlipidemia and Coronary Artery Disease
Patsch, J. R. (1993) · Medical science symposia series · doi:10.1007/978-94-011-1703-6_9 · Cited by 6
Cohn, J. S., & Davignon, J. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)88618-2 · Cited by 5
Self-citationImportant information for contributors
Blombäck, B., & Copley, A. L. (1974) · Thrombosis Research · doi:10.1016/0049-3848(74)90048-6 · Cited by 3
Research works printed but not linked: 2
- Nakajima, 1996, Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apoB-100 and apo AI, J. Clin. Lig. Assay., 19, 177
- McNamara, 1996, Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls, Circulation, 94, I-94
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
McNamara, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00484-6 · Cited by 278
Nakajima, K., Nakano, T., & Tanaka, A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.013 · Cited by 208
Self-citationTwickler, T. B., Dallinga-Thie, G. M., Cohn, J. S., & Chapman, M. J. (2004) · Circulation · doi:10.1161/01.cir.0000125278.58527.f3 · Cited by 201
Self-citationKawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Metadata
- Authors
- Marcoux, C., Tremblay, M., Nakajima, K., Davignon, J., & Cohn, J. S.
- Affiliations
- Montreal Clinical Research Institute (CA)
- Otsuka (United States) (US)
- Corresponding author
- Cohn, Jeffrey S.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 40
- Issue
- 4
- Pages
- 636-647
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2363979887
- Cited by
- 61
- References
- 55
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2012: 1
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7826 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- remnant-like particles, triglyceride-rich lipoproteins, type III hyperlipoproteinemia, type IV hyperlipoproteinemia, hypertriglyceridemia, apolipoprotein E, apolipoprotein C-III, lipoprotein composition, atherogenic lipoproteins
- MeSH terms
- Adult, Apolipoproteins B, Apolipoproteins C, Apolipoproteins E, Cholesterol, Humans, Hyperlipoproteinemia Type III, Hyperlipoproteinemia Type IV, Lipoproteins, Lipoproteins, VLDL, Male, Middle Aged, Particle Size, Triglycerides, Electrophoresis, Gel, Two-Dimensional, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.